» Articles » PMID: 24318992

Association of IL-6 Polymorphisms with Hepatocellular Carcinoma Risk: Evidences from a Meta-analysis

Overview
Journal Tumour Biol
Publisher Sage Publications
Specialty Oncology
Date 2013 Dec 10
PMID 24318992
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The associations between IL-6 gene single nucleotide polymorphisms (SNPs) and risk of hepatocellular carcinoma (HCC) are controversial. We performed a meta-analysis to provide more credible evidence. We searched for relevant studies published up to 2013 by performing an efficient searching strategy. Odds ratios (OR) with 95% confidence interval (95% CI) was used to estimate the strength of the associations between IL-6 polymorphisms and HCC risk. We identified eight case-control studies involving 1,448 HCC cases and 3,160 controls. Our estimation specifically focused on two SNPs of the IL-6 gene, -174 G/C and -572 G/C. The combined results showed that association between IL-6-174 G/C polymorphism and risk of HCC was significant under additive model (CC vs. GG: OR 0.36; 95% CI, 0.16, 0.85) and recessive model (GG+CG vs. CC: OR 2.82; 95% CI 1.26, 6.28). However, the IL-6-572 G/C polymorphism was not associated with HCC risk. In conclusion, IL-6-174 G/C, but not -572 G/C polymorphism could be a candidate for susceptibility to HCC. However, the results should be cautiously interpreted due to the limited number of the included studies.

Citing Articles

Manipulation of Interleukin-6 (IL-6) and Transforming Growth Factor Beta-1(TGFβ-1) towards viral induced liver cancer pathogenesis.

Badshah Y, Shabbir M, Khan K, Fatima M, Majoka I, Aslam L PLoS One. 2022; 17(10):e0275834.

PMID: 36215278 PMC: 9550071. DOI: 10.1371/journal.pone.0275834.


IL-4, IL-17 and CD163 Immunoexpression and IL-6 Gene Polymorphism in Chronic Hepatitis C Patients and Associated Hepatocellular Carcinoma.

Aboushousha T, Emad M, Rizk G, Ragab K, Hammam O, Fouad R Asian Pac J Cancer Prev. 2021; 22(4):1105-1113.

PMID: 33906302 PMC: 8325124. DOI: 10.31557/APJCP.2021.22.4.1105.


Association between interleukin 6 polymorphisms (rs1800796, rs1800795, rs2069837, rs17147230, and rs1800797) and hepatocellular carcinoma susceptibility: a meta-analysis.

Aleagha O, Oltulu P, Sadeghi M Clin Exp Hepatol. 2021; 6(4):359-366.

PMID: 33511285 PMC: 7816640. DOI: 10.5114/ceh.2020.102171.


Association of interleukin-6 gene polymorphisms with the risk of hepatocellular carcinoma: An up-to-date meta-analysis.

An P, Feng L, Zhang X, Jin Q Medicine (Baltimore). 2020; 99(50):e23659.

PMID: 33327352 PMC: 7738155. DOI: 10.1097/MD.0000000000023659.


Interleukin-6 gene polymorphisms and susceptibility to liver diseases: A meta-analysis.

Wang X, Yan Z, Ye Q Medicine (Baltimore). 2019; 98(50):e18408.

PMID: 31852161 PMC: 6922363. DOI: 10.1097/MD.0000000000018408.


References
1.
Minton E, Smillie D, Smith P, Shipley S, McKendrick M, Gleeson D . Clearance of hepatitis C virus is not associated with single nucleotide polymorphisms in the IL-1, -6, or -10 genes. Hum Immunol. 2005; 66(2):127-32. DOI: 10.1016/j.humimm.2004.11.001. View

2.
Terry C, Loukaci V, Green F . Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem. 2000; 275(24):18138-44. DOI: 10.1074/jbc.M000379200. View

3.
Naugler W, Karin M . The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med. 2008; 14(3):109-19. DOI: 10.1016/j.molmed.2007.12.007. View

4.
Wong V, Yu J, Cheng A, Wong G, Chan H, Chu E . High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer. 2009; 124(12):2766-70. DOI: 10.1002/ijc.24281. View

5.
Soresi M, Giannitrapani L, DAntona F, Florena A, La Spada E, Terranova A . Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol. 2006; 12(16):2563-8. PMC: 4087989. DOI: 10.3748/wjg.v12.i16.2563. View